Kobo Biotech
AVONLIFESCIENCESLTD NSE
Kobo Biotech
ChemicalsNSE: AVONLIFESCIENCESLTD BSE: 531541 Commodity Chemicals
Key Fundamentals
MicrocapCommodity ChemicalsChemicalsMarket Cap
₹11.30 Cr
Volatility
Low Risk
P/E Ratio
-2.2
EBITDA
₹-0.70 Cr
Return on Equity
-65.6%
Debt to Equity
3.38
Book Value
₹-57.98
52W High
₹9.99
52W Low
₹1.99
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
Revenue Growth
—
Net Income Growth
-6% lower than
3Y
Cash Flow Change
293%
ROE
—
ROCE
—
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.27 | 0.7 | 0.3 | 9.24 | 0.34 | 0.21 | 0.17 | 0.79 | 0.23 | 0.2 | 0.2 | 0.25 | 0.34 |
| Operating Profit | -0.27 | -0.7 | -0.3 | -9.24 | -0.34 | -0.21 | -0.17 | -0.79 | -0.23 | -0.2 | -0.2 | -0.25 | -0.34 |
| Other Income | 0.02 | 0 | 0 | 0 | 0.02 | 0 | 0 | 0 | 0.02 | 0 | 0 | 0 | 0.02 |
| Interest | 0 | 0.13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1.35 | 1.03 | 1.04 | 1.18 | 1.15 | 0.89 | 1.03 | 1 | 1.01 | 1.02 | 1.03 | 1.01 | 1.01 |
| PBT | -1.6 | -1.86 | -1.34 | -10.42 | -1.47 | -1.1 | -1.2 | -1.79 | -1.22 | -1.22 | -1.23 | -1.26 | -1.33 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -1.6 | -1.86 | -1.35 | -10.42 | -1.47 | -1.1 | -1.19 | -1.79 | -1.23 | -1.22 | -1.23 | -1.26 | -1.33 |
| EPS in Rs | -0.67 | -0.78 | -0.57 | -4.37 | -0.62 | -0.46 | -0.5 | -0.75 | -0.52 | -0.51 | -0.52 | -0.53 | -0.56 |
Profit & Loss
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.89 | 29.05 | 32.54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 61.34 | 38.51 | 27.74 | 4.05 | 3.02 | 1.72 | 0.69 | 2.79 | 10.51 | 1.5 | 0.88 | 1.24 |
| Operating Profit | -4.45 | -9.46 | 4.8 | -4.05 | -3.02 | -1.72 | -0.69 | -2.79 | -10.51 | -1.5 | -0.88 | -1.24 |
| OPM % | -7.82% | -32.56% | 14.75% | — | — | — | — | — | — | — | — | — |
| Other Income | 0.18 | 2.6 | 0.42 | 6 | 0.04 | -2.15 | 0.03 | 0.04 | 0.02 | 0.02 | 0.02 | 0.08 |
| Interest | 18.14 | 15.62 | 14.37 | 14.41 | 14.5 | 14.44 | 14.47 | 10.84 | 0.13 | 0 | 0 | 0 |
| Depreciation | 9.62 | 7.78 | 7.31 | 6.78 | 6.44 | 6.15 | 5.88 | 5.64 | 4.61 | 4.07 | 4.07 | 4.07 |
| PBT | -32.03 | -30.26 | -16.46 | -19.24 | -23.92 | -24.46 | -21.01 | -19.23 | -15.23 | -5.55 | -4.93 | -5.23 |
| Tax % | 1.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -32.57 | -30.26 | -16.46 | -19.24 | -23.92 | -24.46 | -21.01 | -19.23 | -15.23 | -5.55 | -4.93 | -5.23 |
| EPS in Rs | -14.48 | -13.45 | -6.94 | -8.08 | -10.04 | -10.27 | -8.82 | -8.07 | -6.39 | -2.33 | -2.07 | -2.2 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22.5 | 22.5 | 23.73 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 |
| Reserves | 22.07 | -8.83 | -17.3 | -42.41 | -66.33 | -90.79 | -112 | -131 | -146 | -152 | -157 | -162 |
| Borrowings | 137 | 142 | 153 | 208 | 222 | 236 | 251 | 261 | 141 | 140 | 140 | 140 |
| Other Liabilities | 97.45 | 95.74 | 101 | 63.2 | 66.48 | 70.04 | 73.54 | 77.26 | 60.89 | 63.47 | 64.62 | 70.04 |
| Total Liabilities | 279 | 252 | 260 | 252 | 246 | 239 | 236 | 231 | 79.18 | 75.33 | 71.4 | 71.59 |
| Fixed Assets | 104 | 95.1 | 87.79 | 81.01 | 74.56 | 68.42 | 62.54 | 56.91 | 41.66 | 37.59 | 33.52 | 29.44 |
| CWIP | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 0 | 0 | 0 | 0 |
| Investments | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 0 | 0 | 0 | 0 |
| Other Assets | 161 | 142 | 158 | 157 | 157 | 157 | 159 | 159 | 37.52 | 37.74 | 37.88 | 42.15 |
| Total Assets | 279 | 252 | 260 | 252 | 246 | 239 | 236 | 231 | 79.18 | 75.33 | 71.4 | 71.59 |
Cash Flow
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 11.02 | 19.32 | 5.62 | 32.3 | 31.47 | 20.95 | 14.48 | 2.51 | 93.76 | 0.87 | 0.2 | 4.18 |
| Investing | -4.71 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.09 | 0 | 0 | 0 |
| Financing | -7 | -20.5 | -5.27 | -32.76 | -31.47 | -20.95 | -14.47 | -1.08 | -120 | -0.87 | -0.15 | 0 |
| Net Cash Flow | -0.69 | -1.18 | 0.35 | -0.46 | 0 | 0 | 0 | 1.43 | -1.43 | 0 | 0.05 | 4.18 |
| Free Cash Flow | 6.31 | 19.32 | 5.62 | 32.3 | 31.47 | 20.95 | 14.48 | 2.51 | 107 | 0.87 | 0.2 | 4.18 |
| CFO/OP | -260 | -204 | 117 | -798 | -1,042 | -1,218 | -2,099 | -90 | -892 | -58 | -23 | -337 |
Ratios
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 419 | 706 | 1,007 | — | — | — | — | — | — | — | — | — |
| Inventory Days | 585 | 896 | 1,039 | — | — | — | — | — | — | — | — | — |
| Days Payable | 405 | 660 | 1,093 | — | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 599 | 943 | 953 | — | — | — | — | — | — | — | — | — |
| Working Capital Days | 26.63 | -277 | -251 | — | — | — | — | — | — | — | — | — |
| ROCE % | -7.12% | -10.18% | -1.33% | -2.77% | -5.11% | -4.49% | -3.94% | -5.31% | -17.6% | -36.82% | -52.9% | -125.57% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kobo Biotech insights
60 extracted metrics + investor summaries across FY08–FY25.
Documents
1
Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal
8h - NCLT approved Beaufond Industries' resolution plan for Kobo Biotech on 11 May 2026, with 100% CoC vote. 8h - NCLT approved Beaufond Industries' resolution plan for Kobo Biotech on 11 May 2026, with 100% CoC vote.
2
Intimation Regarding Non-Applicability Of Large Entity Disclosure
15 Apr - Company confirmed it is not a Large Corporate as of 31 March 2026. 15 Apr - Company confirmed it is not a Large Corporate as of 31 March 2026.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Compliance certificate under Reg. 74(5) of SEBI (DP) for the quarter ended 31.03.2026 15 Apr - Compliance certificate under Reg. 74(5) of SEBI (DP) for the quarter ended 31.03.2026
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Feb - Certificate under SEBI Regulation 74(5) for quarter ended 31 March 2025. 11 Feb - Certificate under SEBI Regulation 74(5) for quarter ended 31 March 2025.
Frequently Asked Questions about Kobo Biotech
What does Kobo Biotech Ltd do?
Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business[1]
Where is Kobo Biotech Ltd (531541) listed?
Kobo Biotech Ltd trades as AVONLIFESCIENCESLTD on the NSE and under code 531541 on the BSE.
Which sector does Kobo Biotech Ltd belong to?
Kobo Biotech Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the market capitalisation of Kobo Biotech Ltd?
Kobo Biotech Ltd has a market capitalisation of ₹11.3 Cr, which places it in the Small Cap band.
What is the PE ratio of Kobo Biotech Ltd?
Kobo Biotech Ltd trades at a PE ratio of -2.20, against a book value of ₹-57.98 per share.
What is the 52-week high and low of Kobo Biotech Ltd?
Over the last 52 weeks Kobo Biotech Ltd has traded between ₹1.99 and ₹9.99.
What is the Return on Equity (ROE) of Kobo Biotech Ltd?
Kobo Biotech Ltd reported a return on equity of -65.60%. Its debt-to-equity ratio is 3.38.
Company Information
Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business[1]
Website avonlifesciences.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531541.md for Kobo Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.